// App-Quantinova.ai

CT024 : Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)

Researchers

Presenter

  • Karthick Vishwanathan

Principal Investigators

  • James Dunyak

  • Philip Overend

  • Ryan Hartmaier

  • Aleksandra Markovets

  • Juliann Chmielecki

  • Ganesh Mugundu

  • Carl Barrett

  • Helen Tomkinson

  • Martin Johnson

Medical Centers

  • AstraZeneca, Boston, MA

  • AstraZeneca, Waltham, MA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Circulating DNA

Drug/Treatment

  • Tagrisso

  • Erlotinib hydrochloride

  • gefitinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT02296125

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved